NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
- Monday, February 13, 2023, 7:02
- Finance
- Add a comment
FDA discussed a broader indication of “treatment of recently acutely suicidal patients” with Bipolar Depression. This broader indication does not require ketamine as the only stabilization agent. The Company estimates this substantially increases the addressable acute population for its…
About the Author
adminasapcorp has written 41555 stories on this site.